FiercePharma

Teva Receives European Marketing Authorization for DuoResp Spiromax® for the Treatment of Asthma and COPD

JERUSALEM--(BUSINESS WIRE)--Apr. 29, 2014-- Teva Pharmaceutical Industries Ltd., (NYSE:TEVA) announced today that the European Commission has granted marketing authorization for DuoResp Spiromax® for ...
FiercePharma

Teva Receives CHMP Positive Opinion for DuoResp® Spiromax® for the Treatment of Patients Diagnosed with Asthma and COPD in Europe

Teva Receives CHMP Positive Opinion for DuoResp® Spiromax® for the Treatment of Patients Diagnosed with Asthma and COPD in Europe JERUSALEM--(BUSINESS WIRE)--Feb. 21, 2014-- Teva Pharmaceutical ...
Insurancenewsnet.com

Teva’s DuoResp Spiromax® Wins Leading Award for Medical Design Excellence

DuoResp Spiromax ® inhaler has won silver at the 2015 Medical Design Excellence Awards (MDEA). The awards recognize significant advances in medical product design ...